Adavo enhances the cytotoxic effects of 5-fluorouracil in p53-deficient human colon cancer cells, presumably by premature entry into mitosis via inhibition of Cdk1 Tyr15 phosphorylation, induction of histone H3 phosphorylation, abrogation of DNA damage checkpoints, and G2 block [46]. The gene discussed is CDK1; the disease is malignant colon neoplasm.